3 results
Approved WMORecruiting
The purpose of the trial is to compare the safety and effectiveness of bio-active-stent (BAS; Optimax*) and everolimus-eluting stent (EES; Synergy*) in patients presenting with acute coronary syndrome
Approved WMOCompleted
To determine the safety and effectiveness of the PROMUS Element* Everolimus-Eluting Coronary Stent System (Boston Scientific Corporation [BSC], Natick, MA) for the treatment of patients with up to 2 de novo atherosclerotic lesions
Approved WMORecruiting
Primary Objectives:• To assess the efficacy (progression-free survival [PFS]) of DCC-2618 by independent radiologic review in patients with advanced gastrointestinal stromal tumors (GIST) who have previously received first-line therapy with…